NEW YORK, April 17 - Rigel Pharmaceuticals has agreed to license DoubleTwists's Clustering and Alignment Tools (CAT) for organizing expressed sequence tags and mRNA sequences into full-length gene sequences, the companies said Tuesday.

Rigel, based in South San Francisco, will use the tools in bioinformatics analysis of potential drug targets. The company focuses on identifying molecules that regulate a cell's response to disease, and has targeted asthma/allergy, autoimmune, cancer, and other diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.